Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002297409 | SCV002594688 | uncertain significance | Brugada syndrome | 2022-08-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with CACNA2D1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 141 of the CACNA2D1 protein (p.Gly141Arg). |
Ambry Genetics | RCV004603195 | SCV005099790 | uncertain significance | Cardiovascular phenotype | 2024-06-21 | criteria provided, single submitter | clinical testing | The p.G141R variant (also known as c.421G>C), located in coding exon 6 of the CACNA2D1 gene, results from a G to C substitution at nucleotide position 421. The glycine at codon 141 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |